Auranofin is an effective agent against clinical isolates of Staphylococcus aureus

Nagendran Tharmalingam, Noelly Q. Ribeiro, Danielle L. Da Silva, Mandar T. Naik, Lana I.B. Cruz, Wooseong Kim, Steven Shen, Jéssica D. Dos Santos, Katarina Ezikovich, Erika M.C. D'Agata, Eleftherios Mylonakis, Beth B. Fuchs

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Aim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.

Original languageEnglish
Pages (from-to)1417-1425
Number of pages9
JournalFuture Medicinal Chemistry
Volume11
Issue number12
DOIs
StatePublished - 2019

Keywords

  • MRSA
  • Staphylococcus aureus
  • VISA
  • antimicrobial
  • auranofin
  • drug-resistant bacteria
  • thioredoxin reductase

Fingerprint

Dive into the research topics of 'Auranofin is an effective agent against clinical isolates of Staphylococcus aureus'. Together they form a unique fingerprint.

Cite this